Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue SUPPL. 1, 2013, Pages 47-53

  Li, Shi Yan ^a   Liu, Yizhen ^a  

^a Cancer Research Institute   (United States)

Author keywords

anti CD137 monoclonal antibodies; BMS 663513; Immune costimulator molecule

Indexed keywords

CANCER VACCINE; CD137 ANTIBODY; CD137 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; IPILIMUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; RAG1 PROTEIN; RITUXIMAB; SIPULEUCEL T; TICILIMUMAB; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; URELUMAB; VASCULAR CELL ADHESION MOLECULE 1;

ABNORMAL LABORATORY RESULT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL SURVIVAL; CYTOKINE RELEASE; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; INTERFERON PRODUCTION; LEUKOPENIA; MELANOMA; MORTALITY; NATURAL KILLER CELL; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RASH; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 84884822262     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S46199     Document Type: Review

References (50)

1. Rainmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP. Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy. 2013;5(2):169-182.
2. Lee C, Collichio F, Ollila D, Moschos S. Historical review of melanoma treatment and outcomes. Clin Dermatol. 2013;31(2):141-147.
3. Lee AF, Sieling PA, Lee DJ. Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology. 2013;2(2):e22889.
4. Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol. 2012;23 Suppl 8:viii15-viii21.
5. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol. 2012;23 Suppl 8:viii10-viii14.
6. Kushnir I, Merimsky O. The evolution in melanoma treatment as a reflection of precision-oriented medicine. Oncol Lett. 2013;5(2):424-426.
7. Ribas A. Update on immunotherapy for melanoma. J Natl Compr Canc Netw. 2006;4(7):687-694.
8. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
9. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev. 2007;220:82-101.
10. Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A. Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev. 2008;60(2):173-183.
11. Chaudhuri D, Suriano R, Mittelman A, Tiwari RK. Targeting the immune system in cancer. Curr Pharm Biotechnol. 2009;10(2):166-184.
12. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759-767.
13. Hersey P. Immunotherapy of melanoma. Asia Pac J Clin Oncol. 2010;6 Suppl 1:S2-S8.
14. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010;37(5):508-516.
15. Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 2004;11(3):215-226.
16. Nam KO, Kang WJ, Kwon BS, Kim SJ, Lee HW. The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 2005;5(5):357-363.
17. Sun Y, Chen JH, Fu Y. Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol Immunol. 2004;1(1):31-36.
18. Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev. 2008;222: 277-286.
19. Lee SW, Croft M. 4-1BB as a therapeutic target for human disease. Adv Exp Med Biol. 2009;647:120-129.
20. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther. 2012;11(5):1062-1070.
21. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(6):682-685.
22. Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med. 1999;190(10):1535-1540.
23. Sabel MS, Conway TF, Chen FA, Bankert RB. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. J Immunother. 2000;23(3):362-368.
24. Kim JA, Averbook BJ, Chambers K, et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res. 2001;61(5):2031-2037.
25. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002;109(5):651-659.
26. May KF, Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 2002;62(12):3459-3465.
27. Miller RE, Jones J, Le T, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol. 2002;169(4):1792-1800.
28. Ju SA, Cheon SH, Park SM, et al. Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int J Cancer. 2008;122(12):2784-2790.
29. Palazón A, Teijeira A, Martínez-Forero I, et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 2011;71(3):801-811.
30. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117(6):1466-1476.
31. Hernandez-Chacon JA, Li Y, Wu RC, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother. 2011;34(3):236-250.
32. Zhu BQ, Ju SW, Shu YQ. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses. Biomed Pharmacother. 2009;63(7):509-516.
33. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153(4): 1687-1696.
34. Verneris MR, Arshi A, Edinger M, et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res. 2005;11(12):4561-4570.
35. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95-106.
36. Ito F, Li Q, Shreiner AB, et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 2004;64(22):8411-8419.
37. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 2006;12(6):693-698.
38. Kocak E, Lute K, Chang X, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006;66(14):7276-7284.
39. Kim YH, Choi BK, Kim KH, Kang SW, Kwon BS. Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res. 2008;68(18):7264-7269.
40. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol. 1999;162(9):5037-5040.
41. Wilcox RA, Tamada K, Flies DB, et al. Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood. 2004;103(1):177-184.
42. Bristol-Myers Squibb. Study of BMS-663513 in Patients With Advanced Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00309023.NLM identifier: NCT00309023. Accessed July 20, 2013.
43. Melero I, Murillo O, Dubrot J, Hervás-Stubbs S, Perez-Gracia JL. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 2008;29(8):383-390.
44. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) [Abstract]. J Clin Oncol (Meeting Abstracts). 2008;26(Suppl 15):3007.
45. Bristol-Myers Squibb. Phase II, 2nd Line Melanoma-RAND Monotherapy. Available from: http://clinicaltrials.gov/show/NCT00612664. NLM identifier: NCT00612664. Accessed July 30, 2013.
46. Bristol-Myers Squibb. Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma. Available from: http://clinicaltrials.gov/show/NCT01471210. NLM identifier: NCT01471210. Accessed July 20, 2013.
47. Bristol-Myers Squibb. Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL. Available from: http://clinicaltrials.gov/show/NCT01775631. NLM identifier: NCT01775631. Accessed July 20, 2013.
48. Bristol-Myers Squibb. A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies. Available from: http://clinicaltrials.gov/show/NCT00351325. NLM identifier: NCT00351325. Accessed July 20, 2013.
49. Bristol-Myers Squibb. A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC). Available from: http://clinicaltrials.gov/ct2/show/NCT00461110. NLM identifier: NCT00461110. Accessed July 20, 2013.
50. Bristol-Myers Squibb. Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00803374. NLM identifier: NCT00803374. Accessed July 20, 2013.